BIAF has been granted a new patent
Sep 18, 2024, 10:42 PM
15.76%
What does BIAF do
bioAffinity Technologies, based in San Antonio, Texas, focuses on non-invasive early-stage cancer diagnosis and treatment, employing 75 staff since its IPO on August 26, 2022. Its first product, CyPath Lung, aids in detecting early-stage lung cancer, enhancing patient intervention decisions.
BIAF filed a patent for "compositions and methods for use in flow cytometry" on Fri, May 17, 2024. The patent was officially published on Thu, September 12, 2024.
📡️ Health Care
Patents
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
Cashu is the #1 way to stay ahead of the markets, know why your favourite stocks are moving and access valuation signals that smash the market.